Last reviewed 2026-06-10 · How we verify

Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy — Treatment Landscape & Competitive Intelligence

Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dat

Marketed treatment landscape

Approved drugs treating Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy:

• Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy treatment updates — RSS
• Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy treatment updates — Atom
• Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy treatment updates — JSON

Cite this brief

Drug Landscape (2026). Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pembrolizumab-plus-chemotherapy-for-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-who-are-not-eligible-for-any-platinum-containing-chemotherapy. Accessed 2026-06-10.

Related

• Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing